AVDL 13.90 Avadel Pharmaceuticals plc
| Range: | 9.5-19.09 | Vol Avg: | 926185 | Last Div: | 0 | Changes: | 0.16 |
| Beta: | 1.63 | Cap: | 1.26B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 07 1996 | Empoloyees: | 154 | ||
| CUSIP: | 05337M104 | CIK: | 0001012477 | ISIN: | US05337M1045 | Country: | IE |
| CEO: | Mr. Gregory J. Divis Jr. | Website: | https://www.avadel.com | ||||
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Stock Details
AVDL 27
Avadel Pharmaceuticals (AVDL) PT Raised to $27 at H.C. Wainwright
Oren Livnat·Thu May 09 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow